Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (54${count})

  • Target Validation, 2011
    Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief

    Objective/Rationale:
    Endogenous activation of the Delta opioid receptor (DOR) serves as a compensatory mechanism to alleviate Parkinson’s disease (PD) symptoms. However, DOR-mediated convulsions have...

  • Rapid Response Innovation Awards, 2007
    Understanding the Molecular and Functional Changes of CB1/D2/A2A Receptor Complexes in the Hemi-parkinsonian Pre-clinical Model

    Objective/Rationale:
    Future therapies in Parkinson’s disease (PD) may derive from the existence of intramembrane heteromeric receptor complexes containing the dopamine D2 receptor. The ability of...

  • Clinical Intervention Awards, 2007
    The PARKFIT Study: Effectiveness of an Active Lifestyle Promotion Program for Patients with Parkinson’s disease

    Objective/Rationale:
    Parkinson's patients are inclined toward a sedentary lifestyle. This is due to a combination of both physical handicaps (e.g. walking difficulties) and mential impairments (e.g...

  • Research Grant, 2010
    Longitudinal Follow-Up of Clinical and Neuroimaging Signs and Biomarkers in Symptoms & Side Effects and aSymptoms & Side Effects LRRK2 Mutation Carriers in Comparison to Idiopathic PD and Controls

    Objective/Rationale
    Parkinson’s disease (PD) is a common neurodegenerative disease that leads to progressive motor impairment as well as autonomic and cognitive disturbances. The cause of most of...

  • Rapid Response Innovation Awards, 2014
    Disease-modifying Potential of Nortriptyline in Parkinson’s Disease

    Objective/Rationale:             
    Aggregation of the protein alpha-synuclein is toxic to dopamine neurons. Therefore, a compound that reduces or clears this protein could be a viable therapeutic option...

  • Defining Cognitive Phenotypes of Parkinson’s Disease, 2011
    Predicting Cognitive Profiles in Parkinson's Disease: A Multimodal Approach

    Objective/Rationale:
    Our proposal aims to determine the optimum combination of techniques to detect rate of cognitive decline in people with newly diagnosed Parkinson’s disease (PD). We will apply...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.